Valuation: Arcutis Biotherapeutics, Inc.

Market Cap 3.41B 3.06B 2.8B 2.55B 4.81B 321B 4.97B 33.73B 13.45B 171B 12.82B 12.54B 541B P/E 2026 *
68.4x
P/E 2027 * 21x
Enterprise Value 3.13B 2.8B 2.56B 2.34B 4.41B 294B 4.55B 30.88B 12.32B 157B 11.73B 11.48B 495B EV / Sales 2026 *
5.77x
EV / Sales 2027 * 3.99x
Free-Float
98.24%
Yield 2026 *
-
Yield 2027 * -
1 day-5.37%
1 week-20.33%
Current month-20.33%
1 month+6.81%
3 months-3.33%
6 months+5.71%
Current year-12.02%
1 week 25.29
Extreme 25.29
34.8
1 month 23.37
Extreme 23.37
34.8
Current year 19.3
Extreme 19.295
34.8
1 year 19.3
Extreme 19.295
34.8
3 years 1.76
Extreme 1.76
34.8
5 years 1.76
Extreme 1.76
34.8
10 years 1.76
Extreme 1.76
40.88
Manager TitleAgeSince
Chief Executive Officer 58 01/04/2017
Corporate Officer/Principal 71 03/12/2025
Director of Finance/CFO - 15/05/2025
Director TitleAgeSince
Chairman 55 01/12/2019
Director/Board Member 58 01/01/2016
Director/Board Member 74 01/08/2020
Date Insider Type Main position Quantity % Market Cap. Importance
16/9/26 Sell

General Counsel

-3,674 0.0029%
15/9/26 Exercice

Director

12,922 0.0103%
8/9/26 Sell

General Counsel

-9,989 0.0079%
Change 5-day change 1-year change 3-year change Capi.($)
-5.37%-20.33%+1.79%+991.88% 3.41B
-0.79%-4.48%+44.44%+127.49% 1,216B
+1.43%+1.11%+47.73%+82.08% 656B
+1.07%-1.21%+32.99%+106.31% 509B
-0.36%-3.25%+47.17%+64.58% 384B
-0.14%-1.87%+71.05%+40.63% 362B
-0.78%-0.52%+30.57%+57.98% 311B
-0.80%+6.73%+11.89%+35.64% 293B
+0.03%-1.20%+45.89%+68.76% 249B
-0.41%-2.22%+35.24%+105.68% 208B
Average -0.82%-1.01%+36.88%+168.10% 419.12B
Weighted average by Cap. -0.31%+0.02%+42.40%+89.09%

Financials

2026 *2027 *
Net sales 542M 486M 444M 406M 764M 50.94B 788M 5.35B 2.14B 27.18B 2.03B 1.99B 85.81B 696M 624M 570M 521M 981M 65.4B 1.01B 6.87B 2.74B 34.89B 2.61B 2.56B 110B
Net income 53.19M 47.71M 43.6M 39.8M 74.99M 5B 77.35M 526M 210M 2.67B 200M 195M 8.42B 173M 156M 142M 130M 244M 16.3B 252M 1.71B 683M 8.7B 651M 637M 27.46B
Net Debt -288M -259M -236M -216M -407M -27.11B -419M -2.85B -1.14B -14.47B -1.08B -1.06B -45.67B -638M -572M -523M -477M -899M -59.95B -927M -6.3B -2.51B -31.99B -2.39B -2.34B -101B
Projected Income Statement - Annual - Arcutis Biotherapeutics, Inc.
Logo Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company develops therapies against biologically validated targets and produces a pipeline for a range of inflammatory dermatological conditions. Its portfolio consists of topical and systemic treatments to treat immune-mediated dermatological diseases and conditions. Its product portfolio includes ZORYVE Roflumilast Cream, ZORYVE Roflumilast Foam, and ARQ-234. The ZORYVE Roflumilast Cream is used for the treatment of seborrheic dermatitis in individuals aged 9 years and older. The ZORYVE Roflumilast Foam for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older. The ARQ-234 is a fusion protein that is a checkpoint agonist of the CD200 Receptor (CD200R). CD200R is an immune-regulatory receptor which is an immunological checkpoint with a role in the maintenance of immune tolerance.
Employees
354
Date Price Change Volume
07/11/26 US$25.55 -5.37% 3,262,134
05/11/26 US$27.00 -20.70% 7,602,220
04/11/26 US$34.05 +6.41% 2,747,440
03/11/26 US$32.00 +2.37% 1,617,403
02/11/26 US$31.26 -2.53% 1,514,595
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Arcutis Biotherapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
27.00USD
Average target price
39.12USD
Spread / Average Target
+44.91%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Arcutis Biotherapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ARQT Stock